Home > In process > Comparing and combining TSPO-PET tracers in tauopathies. > print

001     285003
005     20260202112928.0
024 7 _ |a 10.1007/s00259-025-07579-3
|2 doi
024 7 _ |a pmid:41114734
|2 pmid
024 7 _ |a 1619-7070
|2 ISSN
024 7 _ |a 1619-7089
|2 ISSN
037 _ _ |a DZNE-2026-00137
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Crook, Harry
|b 0
245 _ _ |a Comparing and combining TSPO-PET tracers in tauopathies.
260 _ _ |a Heidelberg [u.a.]
|c 2026
|b Springer-Verl.
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1770027558_15532
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Neuroinflammation is a key pathological driver in neurodegenerative diseases, including Alzheimer's disease (AD) and Progressive Supranuclear Palsy (PSP). Positron emission tomography (PET) with tracers targeting the translocator protein (TSPO) enables the in vivo quantification of microgliosis. TSPO tracers have shown similar disease-specific patterns across cohorts. However, direct quantitative comparisons between commonly used TSPO-PET tracers in tauopathies have not been performed. Here, we apply a TSPO-PET standardization pipeline across clinically matched AD cohorts and PSP cohorts, to quantify, compare and combine multi-centre TSPO-PET data.Patients with PSP were scanned with either [11C]PK11195 or [18F]GE-180 at one of two centres, while patients with AD and control participants were scanned with either [11C]PK11195, [18F]GE-180 or [11C]PBR28 at one of three centres. A standardised pre-processing pipeline was implemented and participant standardised uptake volume ratio (SUVR) values were z-scored using tracer-specific control participant values. In a data-driven approach, dissimilarity analyses were employed to assess differences between tracers across clinically matched cohorts.In PSP, dissimilarity analysis suggested that [11C]PK11195 and [18F]GE-180 binding patterns were comparable following standardisation. In AD, comparability across tracers was less robust, with [11C]PK11195 and [18F]GE-180 being most comparable, followed by [18F]GE-180 vs. [11C]PBR28, then by [11C]PK11195 vs. [11C]PBR28.The pipeline was effective at harmonising TSPO-PET tracers and standardising the regional quantification of neuroinflammation in clinically matched cohorts of PSP, while the standardisation pipeline results were less robust across AD cohorts.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 1
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Alzheimer’s disease.
|2 Other
650 _ 7 |a Neuroinflammation
|2 Other
650 _ 7 |a Positron emission tomography
|2 Other
650 _ 7 |a Progressive supranuclear palsy
|2 Other
650 _ 7 |a Translocator protein
|2 Other
650 _ 7 |a Receptors, GABA
|2 NLM Chemicals
650 _ 7 |a TSPO protein, human
|2 NLM Chemicals
650 _ 7 |a Radioactive Tracers
|2 NLM Chemicals
650 _ 7 |a PK 11195
|0 YNF83VN1RL
|2 NLM Chemicals
650 _ 7 |a GE-180
|2 NLM Chemicals
650 _ 7 |a Radiopharmaceuticals
|2 NLM Chemicals
650 _ 7 |a Carbazoles
|2 NLM Chemicals
650 _ 7 |a Isoquinolines
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Positron-Emission Tomography: methods
|2 MeSH
650 _ 2 |a Positron-Emission Tomography: standards
|2 MeSH
650 _ 2 |a Receptors, GABA: metabolism
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Radioactive Tracers
|2 MeSH
650 _ 2 |a Tauopathies: diagnostic imaging
|2 MeSH
650 _ 2 |a Tauopathies: metabolism
|2 MeSH
650 _ 2 |a Alzheimer Disease: diagnostic imaging
|2 MeSH
650 _ 2 |a Alzheimer Disease: metabolism
|2 MeSH
650 _ 2 |a Radiopharmaceuticals
|2 MeSH
650 _ 2 |a Carbazoles
|2 MeSH
650 _ 2 |a Isoquinolines
|2 MeSH
700 1 _ |a Franzmeier, Nicolai
|b 1
700 1 _ |a Rahmouni, Nesrine
|b 2
700 1 _ |a Gnoerich, Johannes
|0 P:(DE-2719)9001652
|b 3
|u dzne
700 1 _ |a Fryer, Tim D
|b 4
700 1 _ |a Hong, Young T
|b 5
700 1 _ |a Roemer-Cassiano, Sebastian N
|b 6
700 1 _ |a Palleis, Carla
|0 P:(DE-2719)9000852
|b 7
|u dzne
700 1 _ |a Strauss, Alexandra
|b 8
700 1 _ |a Jones, P Simon
|b 9
700 1 _ |a Aigbirhio, Franklin I
|b 10
700 1 _ |a Hopewell, Robert
|b 11
700 1 _ |a Rauchmann, Boris Stephan
|0 P:(DE-2719)9001808
|b 12
|u dzne
700 1 _ |a Massarweh, Gassan
|b 13
700 1 _ |a Perneczky, Robert
|0 P:(DE-2719)2812234
|b 14
|u dzne
700 1 _ |a Levin, Johannes
|0 P:(DE-2719)2811659
|b 15
|u dzne
700 1 _ |a Höglinger, Günter U
|0 P:(DE-2719)2811373
|b 16
|u dzne
700 1 _ |a Rowe, James B
|b 17
700 1 _ |a O'Brien, John T
|b 18
700 1 _ |a Rosa-Neto, Pedro
|b 19
700 1 _ |a Brendel, Matthias
|0 P:(DE-2719)9001539
|b 20
|u dzne
700 1 _ |a Malpetti, Maura
|0 0000-0001-8923-9656
|b 21
773 _ _ |a 10.1007/s00259-025-07579-3
|g Vol. 53, no. 3, p. 2083 - 2098
|0 PERI:(DE-600)2098375-X
|n 3
|p 2083 - 2098
|t European journal of nuclear medicine and molecular imaging
|v 53
|y 2026
|x 1619-7070
856 4 _ |u https://pub.dzne.de/record/285003/files/DZNE-2026-00137.pdf
|y Restricted
856 4 _ |u https://pub.dzne.de/record/285003/files/DZNE-2026-00137.pdf?subformat=pdfa
|x pdfa
|y Restricted
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 3
|6 P:(DE-2719)9001652
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)9000852
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 12
|6 P:(DE-2719)9001808
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 14
|6 P:(DE-2719)2812234
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 15
|6 P:(DE-2719)2811659
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 16
|6 P:(DE-2719)2811373
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 20
|6 P:(DE-2719)9001539
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 1
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2025-11-07
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2025-11-07
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-11-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-11-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-11-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2025-11-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-11-07
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-11-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-11-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2025-11-07
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EUR J NUCL MED MOL I : 2022
|d 2025-11-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2025-11-07
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2025-11-07
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b EUR J NUCL MED MOL I : 2022
|d 2025-11-07
920 1 _ |0 I:(DE-2719)1111015
|k Clinical Research (Munich)
|l Clinical Research (Munich)
|x 0
920 1 _ |0 I:(DE-2719)5000022
|k AG Dichgans
|l Vascular Cognitive Impairment & Post-Stroke Dementia
|x 1
920 1 _ |0 I:(DE-2719)1111016
|k AG Levin
|l Clinical Neurodegeneration
|x 2
920 1 _ |0 I:(DE-2719)1110007
|k AG Haass
|l Molecular Neurodegeneration
|x 3
980 _ _ |a journal
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a I:(DE-2719)1111015
980 _ _ |a I:(DE-2719)5000022
980 _ _ |a I:(DE-2719)1111016
980 _ _ |a I:(DE-2719)1110007
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21